ライフサイエンスコーパス: Mycobacterium bovis

1 badgers Meles meles naturally infected with Mycobacterium bovis.

2 culosis (TB) is a zoonotic disease caused by Mycobacterium bovis.

3 the most frequently recognized antigens from Mycobacterium bovis.

4 with a strain of M. tuberculosis rather than Mycobacterium bovis.

5 ly differentiate between M. tuberculosis and Mycobacterium bovis.

6 approach and applied it to gene deletions in Mycobacterium bovis.

7 f gammadelta T cells in cattle infected with Mycobacterium bovis.

8 hallenge with purified protein derivative of Mycobacterium bovis.

9 lowing experimental infection of cattle with Mycobacterium bovis.

10 and intractable disease of cattle caused by Mycobacterium bovis.

11 h as Leishmania major, Escherichia coli, and Mycobacterium bovis.

12 is operon is specific to M. tuberculosis and Mycobacterium bovis.

13 he principal sigma factor (RpoV) of virulent Mycobacterium bovis, a member of the Mycobacterium tuber

14 Mycobacterium africanum (subtypes I and II), Mycobacterium bovis (along with the attenuated M. bovis

15 ity was observed with some compounds against Mycobacterium bovis and also against hepatitis C virus i

16 and detection platform for the diagnosis of Mycobacterium bovis and Brucella abortus infection simul

17 ere used to distinguish M. tuberculosis from Mycobacterium bovis and determine phylogenetic lineage.

18 H37Rv isolate and showed 99% identity to the Mycobacterium bovis and M. bovis BCG isolate sequences.

19 It was confirmed to be specific for Mycobacterium bovis and M.caprae cells.

20 ized in the same way that molecular types of Mycobacterium bovis are geographically localized in catt

21 ld badger population naturally infected with Mycobacterium bovis as an example.

22 ability of whole blood to restrict growth of Mycobacterium bovis bacille Calmette Guerin and Mycobact

23 Vaccination with Mycobacterium bovis bacille Calmette-Guerin (BCG) has va

24 uency and numbers of CD8 T cells specific to Mycobacterium bovis bacille Calmette-Guerin (BCG) in the

25 ial activity against Mycobacterium avium and Mycobacterium bovis Bacille Calmette-Guerin (BCG) in vit

26 tion can interact with T cells responding to Mycobacterium bovis bacille Calmette-Guerin (BCG) infect

27 cts of an experimental iron-enriched diet on Mycobacterium bovis bacille Calmette-Guerin (BCG) infect

28 lta T cells displayed major expansion during Mycobacterium bovis Bacille Calmette-Guerin (BCG) infect

29 Because Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccin

30 e and often poor protection conferred by the Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccin

31 immunity could be assessed using intradermal Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccin

32 Analysis of Mycobacterium smegmatis and Mycobacterium bovis bacille Calmette-Guerin (BCG), which

33 mice that were intracerebrally infected with Mycobacterium bovis bacille Calmette-Guerin (BCG).

34 xhibited nanomolar in vitro activity against Mycobacterium bovis bacille Calmette-Guerin and virulent

35 Herein, we demonstrate that exposure of Mycobacterium bovis Bacille Calmette-Guerin or Mycobacte

36 Infection with Mycobacterium bovis bacille Calmette-Guerin resulted in

37 uperinfecting Mycobacterium tuberculosis and Mycobacterium bovis bacille Calmette-Guerin similarly ho

38 mycobacteria, Mycobacterium tuberculosis and Mycobacterium bovis bacille Calmette-Guerin, release MVs

39 CCR4 in response to pulmonary infection with Mycobacterium bovis Bacille-Calmette-Guerin (BCG).

40 e were inoculated with an attenuated form of Mycobacterium bovis, bacille Calmette-Guerin (BCG).

41 ed (TNF-knockout (KO)) mice with recombinant Mycobacterium bovis bacillus Calmette Guerin (BCG) expre

42 DNA vaccination combined with Mycobacterium bovis bacillus Calmette Guerin (BCG) repre

43 We screened 3,290 mutant Mycobacterium bovis bacillus Calmette Guerin (BCG) strai

44 the protection afforded by immunization with Mycobacterium bovis bacillus Calmette-Guerin (BCG) admin

45 Candidate vaccines, based upon Mycobacterium bovis bacillus Calmette-Guerin (BCG) all i

46 AS01B, and compared this to vaccination with Mycobacterium bovis bacillus Calmette-Guerin (BCG) alone

47 these questions, cattle were vaccinated with Mycobacterium bovis bacillus Calmette-Guerin (BCG) and w

48 was phosphorylated in vivo when expressed in Mycobacterium bovis bacillus Calmette-Guerin (BCG) but n

49 nature of the peripheral cell wall lipids of Mycobacterium bovis bacillus Calmette-Guerin (BCG) by co

50 Intravesical administration of Mycobacterium bovis bacillus Calmette-Guerin (BCG) conti

51 Mycobacterium bovis bacillus Calmette-Guerin (BCG) has b

52 rial antigens on the intracellular growth of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in hu

53 Mycobacterium tuberculosis and Mycobacterium bovis bacillus Calmette-Guerin (BCG) induc

54 o track expression of the cytokine following Mycobacterium bovis bacillus Calmette-Guerin (BCG) infec

55 thway of macrophage activation during murine Mycobacterium bovis bacillus Calmette-Guerin (BCG) infec

56 Mycobacterium bovis bacillus Calmette-Guerin (BCG) is th

57 ty-one controls were neither vaccinated with Mycobacterium bovis bacillus Calmette-Guerin (BCG) nor t

58 s of TNF and TNF receptors in the control of Mycobacterium bovis bacillus Calmette-Guerin (BCG) pleur

59 e bone marrow-derived DCs infected with live Mycobacterium bovis Bacillus Calmette-Guerin (BCG) produ

60 Vaccination with Mycobacterium bovis bacillus Calmette-Guerin (BCG) remai

61 on heterologous prime-boost protocols using Mycobacterium bovis bacillus Calmette-Guerin (BCG) to pr

62 n immunodeficiency virus, and the failure of Mycobacterium bovis bacillus Calmette-Guerin (BCG) to pr

63 Mycobacterium bovis Bacillus Calmette-Guerin (BCG) use i

64 d the ability of human antibodies induced by Mycobacterium bovis bacillus Calmette-Guerin (BCG) vacci

65 Mycobacterium bovis bacillus Calmette-Guerin (BCG) vacci

66 Moreover, improved Mycobacterium bovis bacillus Calmette-Guerin (BCG) vacci

67 eprae, Mycobacterium tuberculosis (Mtb), and Mycobacterium bovis bacillus Calmette-Guerin (BCG) were

68 eleted from the genome of the vaccine strain Mycobacterium bovis bacillus Calmette-Guerin (BCG), and

69 ients, yet the current tuberculosis vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is c

70 The only vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is l

71 rating exudate macrophages to infection with Mycobacterium bovis bacillus Calmette-Guerin (BCG), peak

72 g a strain deleted for the KATmt ortholog in Mycobacterium bovis Bacillus Calmette-Guerin (BCG), we s

73 A recognized inducer of Th1 immunity is Mycobacterium bovis bacillus Calmette-Guerin (BCG), whic

74 Here, we demonstrate that Mycobacterium bovis bacillus Calmette-Guerin (BCG)-media

75 cine for tuberculosis is the live attenuated Mycobacterium bovis bacillus Calmette-Guerin (BCG).

76 4(+) T cells during pulmonary infection with Mycobacterium bovis bacillus Calmette-Guerin (BCG).

77 n Mycobacterium smegmatis (M. smegmatis) and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

78 omoides polygyrus bakeri on Th1 responses to Mycobacterium bovis bacillus Calmette-Guerin (BCG).

79 G and NE in the pulmonary resistance against Mycobacterium bovis bacillus Calmette-Guerin (BCG).

80 r-susceptible to infection by Mycoplasma and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

81 (Mphi) isolated from mice given heat-killed Mycobacterium bovis bacillus Calmette-Guerin (HK-BCG) i.

82 In this report, Mycobacterium bovis bacillus Calmette-Guerin and M. tube

83 the human immune responses to infection with Mycobacterium bovis bacillus Calmette-Guerin and Mycobac

84 f mice made immune by prior vaccination with Mycobacterium bovis bacillus Calmette-Guerin compared wi

85 Comparable infection by Mycobacterium bovis bacillus Calmette-Guerin failed to i

86 ncurrent Th1 responses to influenza virus or Mycobacterium bovis bacillus Calmette-Guerin had no effe

87 MHC-restricted T cells during infection with Mycobacterium bovis bacillus Calmette-Guerin in mice.

88 In contrast, the attenuated Mycobacterium bovis bacillus Calmette-Guerin induces les

89 Following Mycobacterium bovis bacillus Calmette-Guerin infection a

90 unt adaptive immune responses in response to Mycobacterium bovis bacillus Calmette-Guerin infections.

91 tion of M. leprae DNA enhanced nonpathogenic Mycobacterium bovis bacillus Calmette-Guerin intracellul

92 ined the set of genes required for growth of Mycobacterium bovis bacillus Calmette-Guerin on minimal

93 mediated immunity by live attenuated vaccine Mycobacterium bovis bacillus Calmette-Guerin or the adop

94 36-wk-old infants, was incubated with viable Mycobacterium bovis bacillus Calmette-Guerin or TLR liga

95 after aerosol immunization with recombinant Mycobacterium bovis bacillus Calmette-Guerin overexpress

96 ine model that involves immunizing mice with Mycobacterium bovis bacillus Calmette-Guerin to augment

97 genous Ag-specific CD4(+) T cells induced by Mycobacterium bovis bacillus Calmette-Guerin vaccination

98 ion of mice with the intracellular bacterium Mycobacterium bovis bacillus Calmette-Guerin, macrophage

99 cobacterium tuberculosis and by bcg_1279c in Mycobacterium bovis bacillus Calmette-Guerin, plays an i

100 Mycobacterium bovis bacillus Calmette-Guerin, the only v

101 ating deletion in the related vaccine strain Mycobacterium bovis bacillus Calmette-Guerin.

102 ella enteritidis, Staphylococcus aureus, and Mycobacterium bovis bacillus Calmette-Guerin.

103 erculosis with the attenuated vaccine strain Mycobacterium bovis bacillus Calmette-Guerin.

104 ed with the current live attenuated vaccine, Mycobacterium bovis-bacillus Calmette-Guerin as well as

105 tiate between Mycobacterium tuberculosis and Mycobacterium bovis based on their relative virulence in

106 bit inhibitory ability against the growth of Mycobacterium bovis BCB.

107 ll have to be evaluated against the existing Mycobacterium bovis BCG "gold standard." It is therefore

108 Here, we characterize the glycolipids of Mycobacterium bovis BCG (BCG) that are released into mur

109 We successfully generated recombinant Mycobacterium bovis BCG (rBCG) expressing simian immunod

110 inigenes through combinations of recombinant Mycobacterium bovis BCG (rBCG), electroporated recombina

111 aque models of simian immunodeficiency virus-Mycobacterium bovis BCG (SIV/BCG) coinfection were emplo

112 e subcutaneously immunized with DeltafbpA or Mycobacterium bovis BCG and challenged with M. tuberculo

113 ock-in [KI] mice) to determine resistance to Mycobacterium bovis BCG and M. tuberculosis infections a

114 less efficient in restricting the growth of Mycobacterium bovis BCG and M. tuberculosis.

115 m tuberculosis antigens that are absent from Mycobacterium bovis BCG and most environmental mycobacte

116 Mycobacterium bovis BCG and Mycobacterium tuberculosis p

117 on in vivo, we evaluated the consequences of Mycobacterium bovis BCG and staphylococcal enterotoxin B

118 on of AFB smears, sputum samples spiked with Mycobacterium bovis BCG at 5 x 10(8) CFU/ml produced 16

119 Introduction of these alleles into Mycobacterium bovis BCG attenuated virulence in macropha

120 The phiRv1 element is not only absent from Mycobacterium bovis BCG but is in different locations wi

121 s infection, mice were immunized with viable Mycobacterium bovis BCG by the aerosol or intravenous ro

122 chanically lyse Bacillus subtilis spores and Mycobacterium bovis BCG cells.

123 ciency virus (SIVmac) can develop persistent Mycobacterium bovis BCG coinfection and a fatal SIV-rela

124 of simian immunodeficiency virus (SIV(mac))-Mycobacterium bovis BCG coinfection were employed to exp

125 However, mtFabH overexpression in Mycobacterium bovis BCG did not confer thiolactomycin re

126 Infection by Mycobacterium bovis BCG does not inhibit IFN-alpha-stimu

127 the mycobacterial antigen 85A (rAd85A), with Mycobacterium bovis BCG followed by rAd85A heterologous

128 rs among ~200 binding regions throughout the Mycobacterium bovis BCG genome, were identified using Ch

129 t of exogenous cAMP on protein expression in Mycobacterium bovis BCG grown under hypoxic versus ambie

130 Importantly, preexisting immunity to Mycobacterium bovis BCG had only a marginal effect on th

131 Moreover, a similar screen in Mycobacterium bovis BCG identified that phthiocerol dimy

132 k of macroscopic pathology, and a history of Mycobacterium bovis BCG immunization was associated with

133 ly inhibit intracellular bacterial growth of Mycobacterium bovis BCG in macrophages (MPhi) in cocultu

134 sis of bystander cells to restrict growth of Mycobacterium bovis BCG in monocytes.

135 In this study, we examined the growth of Mycobacterium bovis BCG in the lungs under experimental

136 gen-specific Vgamma2Vdelta2(+) T cells after Mycobacterium bovis BCG infection and BCG reinfection, r

137 In this study we examined the effect of Mycobacterium bovis BCG infection on the L-arginine-depe

138 We examined the role of IL-23 during Mycobacterium bovis BCG infection.

139 Using a Mycobacterium bovis BCG mutant (AS1) lacking a Bacillus

140 letion of the ClpP1P2 level in a conditional Mycobacterium bovis BCG mutant enhanced killing by ADEP

141 We show that an in-frame deletion of Mycobacterium bovis BCG nat results in delayed entry int

142 Treatment of mice with heat-killed (HK) Mycobacterium bovis BCG or 1- to 10-microm chitin partic

143 d iniC (Rv 0341 and Rv 0343) by treatment of Mycobacterium bovis BCG or M. tuberculosis with INH or E

144 mycobacterial strains (Mycobacterium avium, Mycobacterium bovis BCG or Mtb), were exposed to encapsu

145 We found that Mycobacterium bovis BCG or Mycobacterium tuberculosis in

146 put resistance-based phenotypic screen using Mycobacterium bovis BCG over-expressing GuaB2.

147 s of published data for two species; namely, Mycobacterium bovis BCG Pasteur and Mycobacterium smegma

148 n in a PE_PGRS gene (1818(PE_PGRS)) found in Mycobacterium bovis BCG Pasteur, which is the BCG homolo

149 playing a role in the altered maturation of Mycobacterium bovis BCG phagosomes.

150 Mycobacterium bovis BCG responded to each stage of hypox

151 ytes stimulated with M. leprae compared with Mycobacterium bovis BCG stimulation.

152 Attenuation of Mycobacterium bovis BCG strain is related to the loss of

153 this study we observe that strain AS-1, the Mycobacterium bovis BCG strain lacking the Rv0522 gene,

154 phages, attenuated M. tuberculosis H37Ra and Mycobacterium bovis BCG strongly induce THP-1 apoptosis,

155 fected with low or high doses of recombinant Mycobacterium bovis BCG that secreted murine TNF-alpha (

156 NA (rRNA) and tRNA, from mycobacteria, using Mycobacterium bovis BCG to illustrate the method.

157 culosis promoter-lacZ reporter constructs in Mycobacterium bovis BCG under conditions of ambient air

158 5% carbon dioxide was required for growth of Mycobacterium bovis BCG under microaerophilic (1.3% O(2)

159 tensively in assessing novel vaccines, since Mycobacterium bovis BCG vaccination effectively prolongs

160 Although widely used, Mycobacterium bovis BCG vaccination given at birth does

161 The World Health Organization recommends Mycobacterium bovis BCG vaccination in areas of high tub

162 The effect of Mycobacterium bovis BCG vaccination on interleukin-1 bet

163 her primary nor memory immunity conferred by Mycobacterium bovis BCG vaccination was affected in mice

164 To determine whether Mycobacterium bovis BCG vaccination would alter gamma in

165 is, which was comparable to that provided by Mycobacterium bovis BCG vaccination.

166 ctive capacity as a potential adjunct to the Mycobacterium bovis BCG vaccine in the mouse and guinea

167 Mycobacterium bovis BCG vaccine provides only partial pr

168 Three commonly used Mycobacterium bovis BCG vaccine strains elicited differe

169 Beijing lineage strains) may be resistant to Mycobacterium bovis BCG vaccine-induced antituberculosis

170 been vaccinated with the partially effective Mycobacterium bovis BCG vaccine.

171 enerate protection equivalent to that of the Mycobacterium bovis BCG vaccine.

172 ections and do so better than the suboptimal Mycobacterium bovis BCG vaccine.

173 Mycobacterium bovis BCG was cultivated at high and low g

174 The phosphatase activity in whole cells of Mycobacterium bovis BCG was significantly less than that

175 the TPA combination, the Ub combination, and Mycobacterium bovis BCG were able to limit the growth of

176 isolated PAS-resistant transposon mutants of Mycobacterium bovis BCG with insertions in the thymidyla

177 prepared and evaluated for activity against Mycobacterium bovis BCG with the thiourea-containing iso

178 tions, the highly related but non-pathogenic Mycobacterium bovis BCG yields partially ( approximately

179 Previously, we found that Mycobacterium bovis BCG, a human tuberculosis vaccine, s

180 ficient lysis of Mycobacterium tuberculosis, Mycobacterium bovis BCG, and Mycobacterium marinum.

181 atory strains of Mycobacterium tuberculosis, Mycobacterium bovis BCG, and Mycobacterium smegmatis.

182 an macrophages could survive infection, kill Mycobacterium bovis BCG, and severely limit the replicat

183 be propagated in Mycobacterium smegmatis and Mycobacterium bovis BCG, and their compatibility with ot

184 dimycocerosyl phthiocerol, were cloned from Mycobacterium bovis BCG, and their promoters were analyz

185 from virulent M. tuberculosis and attenuated Mycobacterium bovis BCG, bacteria were grown in broth cu

186 The CRP(Mt) ortholog in Mycobacterium bovis BCG, CRP(BCG), is dysfunctional in a

187 A mutant strain of Mycobacterium bovis BCG, defective in the transport of s

188 accine against tuberculosis, live attenuated Mycobacterium bovis BCG, has variable efficacy, but deve

189 ine cocktail or with the current TB vaccine, Mycobacterium bovis BCG, induced considerable antituberc

190 gues exhibited balanced profiles of potency (Mycobacterium bovis BCG, M tuberculosis H37Rv), selectiv

191 g to the Corynebacterineae suborder, namely, Mycobacterium bovis BCG, Mycobacterium smegmatis, and Co

192 Screening for amino acid auxotrophs of Mycobacterium bovis BCG, obtained by transposon mutagene

193 , metabolome profiling in the Mtb surrogate, Mycobacterium bovis BCG, reveals significant changes in

194 st everyone is vaccinated early in life with Mycobacterium bovis BCG, the currently available vaccine

195 4(+) T cells to suppress T cell responses to Mycobacterium bovis BCG, the live vaccine that provides

196 In the lungs of mice vaccinated with Mycobacterium bovis BCG, there was an accumulation of CD

197 ied a new cAMP-associated regulon in Mtb and Mycobacterium bovis BCG, which is distinct from the prev

198 ing and intravital multiphoton microscopy of Mycobacterium bovis BCG-induced liver granulomas.

199 studied granuloma formation after 6 weeks in Mycobacterium bovis BCG-infected CD28- and CD40 ligand (

200 tudy we analyzed humoral immune responses in Mycobacterium bovis BCG-vaccinated and control cattle (i

201 le of splenocytes restimulated in vitro from Mycobacterium bovis BCG-vaccinated and naive animals.

202 macrophages harvested from nonvaccinated and Mycobacterium bovis BCG-vaccinated guinea pigs were infe

203 Mycobacterium bovis BCG-vaccinated guinea pigs were inje

204 immune T cells and macrophages obtained from Mycobacterium bovis BCG-vaccinated guinea pigs.

205 sentially equivalent to the survival time of Mycobacterium bovis BCG-vaccinated mice (294 +/- 15 days

206 To extend these observations to a Mycobacterium bovis BCG-vaccinated population and to ano

207 ne activities in Mycobacterium smegmatis and Mycobacterium bovis BCG.

208 BALB/c mice were infected by aerosol with Mycobacterium bovis BCG.

209 riven by the heat shock promoter, phsp60, of Mycobacterium bovis BCG.

210 wth of extended-stationary-phase cultures of Mycobacterium bovis BCG.

211 icantly enhanced upon prior vaccination with Mycobacterium bovis BCG.

212 sA2, and desA3, were cloned and expressed in Mycobacterium bovis BCG.

213 e individuals or individuals vaccinated with Mycobacterium bovis BCG.

214 ene) by using a promoter-GFP fusion assay in Mycobacterium bovis BCG.

215 d protection equivalent to that conferred by Mycobacterium bovis BCG.

216 ice infected intravenously with 10(5) CFU of Mycobacterium bovis BCG.

217 ce protection equivalent to that produced by Mycobacterium bovis BCG.

218 boosting individuals already inoculated with Mycobacterium bovis BCG.

219 ility of intracellular but not extracellular Mycobacterium bovis BCG.

220 cterium tuberculosis and its close relative, Mycobacterium bovis (BCG) contain five genes whose predi

221 and is not functional in the closely related Mycobacterium bovis because of an inactivating frameshif

222 analyses were used to assess transmission of Mycobacterium bovis between humans.

223 The risk of Mycobacterium bovis bloodstream infection (BSI) in bacil

224 icans hyphae and extracellular aggregates of Mycobacterium bovis, but not in response to small yeast

225 to explore opportunities for transmission of Mycobacterium bovis [causal agent of bovine tuberculosis

226 Mycobacterium bovis causes tuberculosis in a wide variet

227 omagnetic separation (IMS) method to isolate Mycobacterium bovis cells from lymph node tissues.

228 f BCG against Mycobacterium tuberculosis and Mycobacterium bovis challenge in animal models, for effi

229 Bovine tuberculosis (bTB), caused by Mycobacterium bovis, continues to be a serious economic

230 , mycobacterial crude cell wall extract, and Mycobacterium bovis culture filtrate proteins.

231 test is compromised by vaccination with the Mycobacterium bovis-derived vaccine strain bacille Calme

232 , and their assessment as typing tools in 47 Mycobacterium bovis field isolates and nine MTBC strains

233 nt apoptosis as a result of infection with a Mycobacterium bovis field strain.

234 notyping techniques that have differentiated Mycobacterium bovis from Mycobacterium tuberculosis sinc

235 mental models of protective immunity against Mycobacterium bovis: (i) vaccination with M. bovis BCG a

236 t overlap geographically with the strains of Mycobacterium bovis in Great Britain.

237 orescence for rapid, definitive detection of Mycobacterium bovis in lymph node specimens from 38 catt

238 WC1(+) gammadelta T cells of Mycobacterium bovis-infected cattle are highly responsiv

239 Accurately identifying Mycobacterium bovis-infected cattle is critical for bovi

240 s adenylate cyclase (CyaA) are recognized by Mycobacterium bovis-infected cattle more effectively tha

241 Moreover, Mycobacterium bovis-infected IRAK-4-knockout macrophages

242 ngly recognized by cattle with early primary Mycobacterium bovis infection and by healthy MTB-sensiti

243 ods capable of detecting and differentiating Mycobacterium bovis infection from other pathogenic and

244 ategy in countries where there is persistent Mycobacterium bovis infection in wildlife and in develop

245 Promoting effective immunity to Mycobacterium bovis infection is a challenge that is of

246 Current assays used to detect Mycobacterium bovis infection lack accuracy, especially

247 Mycobacterium bovis infection of cattle represents a nat

248 dentify peptides that are immunogenic during Mycobacterium bovis infection of cattle.

249 Disease due to human Mycobacterium bovis infection usually occurs in older pa

250 To estimate mortality for Mycobacterium bovis infections and morbidity and mortali

251 he surface of Mycobacterium tuberculosis and Mycobacterium bovis, initiates responses that can lead b

252 Tuberculosis (TB) caused by Mycobacterium bovis is a re-emerging disease of livestoc

253 Bovine tuberculosis caused by Mycobacterium bovis is a serious and economically import

254 Mycobacterium bovis is best identified by screening thos

255 Mycobacterium bovis is naturally resistant to the antitu

256 Mycobacterium bovis is the causative agent of bovine tub

257 The bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis is used in many parts of the world a

258 Bovine tuberculosis (bTB; Mycobacterium bovis) is a bacterial infection of cattle

259 Calmette-Guerin (BCG), an attenuated form of Mycobacterium bovis, is associated with persistent activ

260 lmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, is widely used as adjunctive therap

261 Mycobacterium bovis isolates carry restricted allelic va

262 dy set of 180 Mycobacterium tuberculosis and Mycobacterium bovis isolates having low copy numbers of

263 the fundamental in vitro characteristics of Mycobacterium bovis--its requirement for pyruvate in gly

264 The attenuated strain of Mycobacterium bovis known as bacille Calmette-Guerin (BC

265 duced greater IL-22 and IL-17A production in Mycobacterium bovis (M. bovis)-infected cattle compared

266 Although the bovine tuberculosis (TB) agent, Mycobacterium bovis, may infect humans and cause disease

267 etween 72 and 96 h), in cattle infected with Mycobacterium bovis (n = 22) and animals sensitized by e

268 s to determine the minimum infective dose of Mycobacterium bovis necessary to stimulate specific immu

269 Mycobacterium bovis produced only low levels of nitrite,

270 ma formation in response to bead-immobilized Mycobacterium bovis-purified protein derivative in aged

271 e to reproducibly generate cavities by using Mycobacterium bovis Ravenel, M. bovis AF2122, M. bovis B

272 .C.13, H37Rv, and H37Ra) and two isolates of Mycobacterium bovis (Ravenel and BCG) to reactive oxygen

273 The data reveal that Mycobacterium bovis RNAP exhibits an unstable RPo that i

274 ty, and both the incidence and prevalence of Mycobacterium bovis show marked variation in space.

275 advantages, we investigated the potential of Mycobacterium bovis-specific antigens to stimulate delay

276 ular composition and bacterial protection in Mycobacterium bovis strain bacille Calmette-Guerin (BCG)

277 both acute and chronic granulomas induced by Mycobacterium bovis strain bacillus Calmette-Guerin (BCG

278 Using a murine model of Mycobacterium bovis strain bacillus Calmette-Guerin (BCG

279 4 as a selective agent, transposon-generated Mycobacterium bovis strain BCG (M. bovis) mutants that c

280 We applied this to cultured Mycobacterium bovis strain BCG DNA and to combined cultu

281 ct 10 colony-forming units of the attenuated Mycobacterium bovis strain BCG in human sputum in the pr

282 Transformation of Mycobacterium bovis strain BCG with M. smegmatis pncA or

283 create a collection of insertion mutants of Mycobacterium bovis strain BCG.

284 city of rough morphology M. tuberculosis and Mycobacterium bovis strains was greater than smooth "M.

285 creasingly recognized MtbC groupings include Mycobacterium bovis subsp. caprae and "Mycobacterium tub

286 ette-Guerin (BCG) is an attenuated strain of Mycobacterium bovis that is used widely as a vaccine for

287 rculosis vaccine, is an attenuated mutant of Mycobacterium bovis that was isolated after serial subcu

288 Mycobacterium bovis, the aetiological agent of bovine tu

289 (Meles meles) are implicated in transmitting Mycobacterium bovis, the causative agent of bovine tuber

290 a series of attempts to limit the spread of Mycobacterium bovis, the causative agent of bovine tuber

291 The incidence of Mycobacterium bovis, the causative agent of bovine tuber

292 The incidence of Mycobacterium bovis, the causative agent of bovine tuber

293 etic relatedness, and elevated prevalence of Mycobacterium bovis, the causative agent of TB.

294 Mycobacterium tuberculosis and Mycobacterium bovis, the causative agents of human and b

295 tantial evidence suggests that the burden of Mycobacterium bovis, the cause of bovine tuberculosis, m

296 ry, one secondary case due to drug-resistant Mycobacterium bovis was found.

297 vage pathway of the bovine tubercle bacillus Mycobacterium bovis was reported defective due to a muta

298 us, 1758) population naturally infected with Mycobacterium bovis, we built an integrated population m

299 fected with either M. avium subsp. avium and Mycobacterium bovis were exposed to the array to identif

300 ore than 50 million cattle are infected with Mycobacterium bovis worldwide, resulting in severe econo